Investing.com - Avita Medical (NASDAQ: RCEL) reported fourth quarter EPS of $-0.28, $0.10 better than the analyst estimate of $-0.38. Revenue for the quarter came in at $14.1M versus the consensus estimate of $14.43M.
Guidance
Avita Medical sees Q1 2024 revenue of $14.80M-$15.60M versus the analyst consensus of $14.30M.
Avita Medical sees FY 2024 revenue of $78.50M-$84.50M versus the analyst consensus of $71.98M.
Avita Medical's stock price closed at $17.01. It is up 58.53% in the last 3 months and up 87.75% in the last 12 months.
Avita Medical saw 3 positive EPS revisions and 2 negative EPS revisions in the last 90 days. See Avita Medical's stock price’s past reactions to earnings here.
According to InvestingPro, Avita Medical's Financial Health score is "good performance".
Check out Avita Medical's recent earnings performance, and Avita Medical's financials here.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com's earnings calendar